STAAR Surgical Company's (NASDAQ:STAA) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
STAAR Surgical Company's (NASDAQ:STAA) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
STAAR Surgical (NASDAQ:STAA) has had a rough month with its share price down 8.7%. However, stock prices are usually driven by a company's financials over the long term, which in this case look pretty respectable. Particularly, we will be paying attention to STAAR Surgical's ROE today.
STAAR Surgical (納斯達克:STAA) 股價在過去一個月內跌了8.7%。然而，股票價格通常長期受一家公司的財務狀況驅動，而在這種情況下這看起來相當可觀。今天我們將重點關注STAAR Surgical的淨資產收益率ROE。
Return on equity or ROE is a key measure used to assess how efficiently a company's management is utilizing the company's capital. Put another way, it reveals the company's success at turning shareholder investments into profits.
股本回報率或roe是一項關鍵指標，用於評估公司管理層使用公司資本的效率。換句話說，它揭示了公司將股東的投資轉化爲利潤的成功。
How To Calculate Return On Equity?
如何計算股東權益報酬率？
Return on equity can be calculated by using the formula:
股東權益報酬率可以使用以下公式計算：
Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity
淨資產收益率 = 淨利潤（從持續經營中獲得）÷ 股東權益
So, based on the above formula, the ROE for STAAR Surgical is:
因此，根據上述公式，STAAR Surgical的ROE爲：
3.9% = US$15m ÷ US$393m (Based on the trailing twelve months to March 2024).
3.9％ = US$15m ÷ US$393m（基於截至2024年3月的過去12個月）。
The 'return' refers to a company's earnings over the last year. So, this means that for every $1 of its shareholder's investments, the company generates a profit of $0.04.
“回報”是指公司過去一年的收益。因此，這意味着對於每個股東的投資1美元，公司會產生0.04美元的利潤。
What Has ROE Got To Do With Earnings Growth?
ROE與盈利增長有什麼關係？
So far, we've learned that ROE is a measure of a company's profitability. We now need to evaluate how much profit the company reinvests or "retains" for future growth which then gives us an idea about the growth potential of the company. Assuming everything else remains unchanged, the higher the ROE and profit retention, the higher the growth rate of a company compared to companies that don't necessarily bear these characteristics.
到目前爲止，我們已經了解到roe是公司利潤能力的一個衡量標準，現在我們需要評估公司再投資或“保留”的利潤，以此來了解公司的增長潛力。假設其他所有因素保持不變，roe和利潤保留率越高，公司的增長速度就越高，相對於不一定具備這些特徵的公司而言。
A Side By Side comparison of STAAR Surgical's Earnings Growth And 3.9% ROE
STAAR Surgical的盈利增長與3.9％的ROE的並列比較
As you can see, STAAR Surgical's ROE looks pretty weak. Even when compared to the industry average of 11%, the ROE figure is pretty disappointing. However, we we're pleasantly surprised to see that STAAR Surgical grew its net income at a significant rate of 24% in the last five years. We reckon that there could be other factors at play here. For instance, the company has a low payout ratio or is being managed efficiently.
正如您所看到的，STAAR Surgical的ROE看起來相當弱。即使與行業平均水平的11％進行比較，ROE的數據也相當令人失望。然而，令人驚喜的是，在過去五年中，STAAR Surgical的淨利潤以顯着的24％的速率增長。我們認爲可能存在其他因素。例如，公司的派息比率較低或被有效率地管理。
As a next step, we compared STAAR Surgical's net income growth with the industry, and pleasingly, we found that the growth seen by the company is higher than the average industry growth of 8.7%.
作爲下一步，我們將STAAR Surgical的淨利潤增長與行業進行比較，並令人高興的是，我們發現該公司所看到的增長高於平均行業增長8.7％。
Earnings growth is a huge factor in stock valuation. It's important for an investor to know whether the market has priced in the company's expected earnings growth (or decline). By doing so, they will have an idea if the stock is headed into clear blue waters or if swampy waters await. Is STAA fairly valued? This infographic on the company's intrinsic value has everything you need to know.
盈利增長是股票估值的一個重要因素。投資者了解市場是否已經將公司預期盈利增長（或下降）的價格計入其中非常重要。通過這樣做，他們將了解股票是朝着明朗的未來發展還是面臨泥濘的未來。STAA的價值是否合理？此信息圖中的公司內在價值包含了您需要了解的所有內容。
Is STAAR Surgical Using Its Retained Earnings Effectively?
STAAR Surgical是否有效地利用了保留收益？
STAAR Surgical doesn't pay any regular dividends currently which essentially means that it has been reinvesting all of its profits into the business. This definitely contributes to the high earnings growth number that we discussed above.
STAAR Surgical目前不支付任何常規股息，這基本上意味着它一直將所有利潤重新投資到業務中。這絕對有助於上述高盈利增長率的數字。
Summary
總的來說，我們對偉明環保的表現非常滿意。具體而言，我們喜歡公司以高回報率再投資了其利潤的很大一部分。當然，這導致公司的收益大幅增長。但是，最新的行業分析師預測表明，該公司的收益預計將加速增長。
Overall, we feel that STAAR Surgical certainly does have some positive factors to consider. With a high rate of reinvestment, albeit at a low ROE, the company has managed to see a considerable growth in its earnings. Having said that, looking at the current analyst estimates, we found that the company's earnings are expected to gain momentum. To know more about the latest analysts predictions for the company, check out this visualization of analyst forecasts for the company.
總的來說，我們認爲STAAR Surgical肯定有一些值得考慮的積極因素。儘管ROE較低，但已經以較高的再投資率實現了可觀的收益增長。話雖如此，根據目前的分析師預測，我們發現公司的盈利預計將增長。了解有關該公司最新分析師預測的更多信息，請查看該公司分析師預測的可視化信息。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有反饋？關於內容有所顧慮？直接和我們聯繫。或者，發送電子郵件至editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論，只使用公正的方法論，我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議，也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意，我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。
譯文內容由第三人軟體翻譯。